Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study to Assess Efficacy and Safety of Atuliflapon Given Orally Once Daily for Twelve Weeks in Adults With Moderate to Severe Uncontrolled Asthma

NCT05251259 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT05251259
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05251259 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study to Assess Efficacy and Safety of Atuliflapon Given Orally Once Daily for Twelve Weeks in Adults With Moderate to Severe Uncontrolled Asthma
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
January 27, 2022
Completion date
January 7, 2026
Enrollment
670 (actual)
Sites
234

Conditions

As the registry lists them; a condition with its own page is linked.

asthma